Project Grant R01HL181444
Award Date 7/9/26
Completion Date 3/31/28
Dollars Obligated $1.6M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Roxbury, MA 02118, USA
Similar Awards
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Boston University Medical Campus a $1.62M Project Grant (CFDA 93.837: Cardiovascular Diseases Research) effective July 7, 2026, through March 31, 2028, to investigate the role of PACC1 (proton-gated chloride channel) in host defense against bacterial infections and sepsis. This research addresses the significant global health burden of sepsis, which causes approximately 50 million annual cases worldwide...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $490,500 Project Grant to Boston University Medical Campus (Trustees of Boston University) beginning September 1, 2025, with a completion date of May 31, 2029, under the Cardiovascular Diseases Research program (CFDA 93.837). The research investigates novel mechanistic insights into inflammation and organ injury resulting from dysregulated host defense in bacterial pneumonia and sepsis....
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Feinstein Institutes for Medical Research a Project Grant of $586,866 under the Cardiovascular Diseases Research program (CFDA 93.837) on May 15, 2026, with a completion date of February 28, 2030. This award funds research investigating the critical role of B-1A cells, an immunoregulatory B cell subset, in mitigating acute lung injury (ALI) and acute respiratory distress...
- Federal Project Grant Award Summary Boston University Medical Campus received a $122,625 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) beginning June 1, 2025 and concluding May 31, 2027. The award funds research and development of novel small molecule therapeutics targeting oxidized sirtuin-1 (SIRT1) as a potential treatment for aortic aneurysms in Marfan Syndrome. The research deliverables...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) awarded Massachusetts General Hospital a Project Grant of $1,579,554 on September 10, 2025, for research concluding June 30, 2030. The award funds an integrated genomic and functional research initiative to decipher the mechanisms underlying chronic obstructive pulmonary disease (COPD) and asthma—two of the most common and costly chronic respiratory...
- Federal Project Grant Award Summary Brigham & Women's Hospital Inc. received a $1.41 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 1, 2025, with completion targeted for May 31, 2029. The award funds research to characterize lung interstitial neutrophils (LINs)—a specialized immune cell subset with enhanced bactericidal capacity. The project investigates the origin,...
- Federal Project Grant Award Summary National Jewish Health received a $1,559,468 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 10, 2026, with a completion date of June 30, 2028. The research investigates the physiological function of MyD88-S (myeloid differentiation factor 88 short form), a protein splice variant that modulates Toll-like receptor signaling in response to pathogenic...
- Federal Project Grant Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Washington University a Project Grant of $680,379 under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 1, 2026, with completion targeted for March 31, 2030. The research project investigates the role of sphingolipid biosynthesis in immune cell function during Mycobacterium tuberculosis (MTB) infection. Specifically, the study examines how SPTLC2—an essential enzyme subunit...
- Federal Project Grant Award Summary Boston University Medical Campus received a $150,342 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 30, 2026, with completion targeted for June 30, 2029. The award funds research investigating the mechanisms of a conserved niche endothelial program that directs hematopoietic stem cell (HSPC) migration into bone marrow during stem cell...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Trustees of Boston University a Project Grant of $166,752 (Award Date: September 1, 2025; Completion Date: August 31, 2027) under the Cardiovascular Diseases Research program (CFDA 93.837) to advance understanding of lung branching morphogenesis through synthetic biology approaches. The research deliverables will include fundamental discoveries regarding the signaling mechanisms—specifically...